Digital monitoring by whole body photography and sequential digital dermoscopy detects thinner melanomas
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Population screening for melanoma remains controversial. There are no studies demonstrating that population screening increases survival. As prognosis of melanoma is directly related to Breslow thickness, a surrogate marker of survival is thickness of melanoma. The development of several self-referred, whole-body photography and sequential digital dermoscopy imaging services reflects the public’s concern regarding melanoma. AIM: To assess the ability of one of these services to detect melanoma at an early, thin stage. METHODS: Demographic and histological details from 100 melanomas diagnosed through self-referred whole-body photography and sequential digital dermoscopy imaging service compared to those diagnosed through traditional methods from data held by the New Zealand Cancer Registry. RESULTS: There were 52 invasive and 48 in-situ melanomas: 90% superficial spreading type, 6% lentigo-maligna type and 4% nodular on histology. Forty-eight were diagnosed on first visit; the remainder by serial digital dermoscopy. Thirty-five percent of patients reported having had previous primary melanoma. In 60%, patients had been concerned by the lesion, the rest (40%) detected solely by screening. Patients diagnosed by whole-body photography and sequential digital dermoscopy screening had thinner melanomas compared to the Registry data: 69% <0.75 mm Breslow thickness compared to 52% (p=0.0216); only 1.9% thicker than 3 mm compared to 10.8% (p=0.067). DISCUSSION: Melanomas detected by self-referred, whole-body photography with sequential digital dermoscopy service are thinner than melanomas detected by traditional diagnostic methods. It remains to be determined whether earlier diagnosis results in improved survival. KEYWORDS: Dermoscopy; mass screening; diagnosis, melanoma; telemedicine; teledermatology
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tan, E., Yung, A., Jameson, M., Oakley, A., & Rademaker, M. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09673.x · Cited by 116
Self-citationGeller, A. C., Elwood, M., Swetter, S. M., Brooks, D. R., Aitken, J., Youl, P. H., Demierre, M., & Baade, P. D. (2009) · Cancer · doi:10.1002/cncr.24162 · Cited by 91
Cited by
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.008 · Cited by 329
The role of technology in melanoma screening and diagnosis
Young, A. T., Vora, N. B., Cortez, J., Tam, A., Yeniay, Y., Afifi, L., Yan, D., Nosrati, A., Wong, A., Johal, A., et al. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12907 · Cited by 60
Survival Is Not the Only Valuable End Point in Melanoma Screening
Curiel-Lewandrowski, C., Kim, C. C., Swetter, S. M., Chen, S. C., Halpern, A. C., Kirkwood, J. M., Leachman, S. A., Marghoob, A. A., Ming, M. E., & Grichnik, J. M. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.3 · Cited by 26
“The added value of this comprehensive approach in the evaluation of high-risk melanoma patients has been documented in both the community dermatology setting (Wang et al., 2004; Rademaker and Oakley, 2010) and particularly in the case of specialized Pigmented Lesion Clinics (Feit et al.”
BackgroundAbbott, L. M., Miller, R., Janda, M., Bennett, H., Taylor, M. L., Arnold, C., Shumack, S., Soyer, H. P., & Caffery, L. J. (2020) · Australasian Journal of Dermatology · doi:10.1111/ajd.13249 · Cited by 26
Metadata
- Authors
- Rademaker, M., & Oakley, A.
- Venue
- The Journal of Primary Health Care
- Publisher
- CSIRO Publishing
- Published
- 2010-12-01
- Volume
- 2
- Issue
- 4
- Pages
- 268-272
- ISSN
- 1172-6156 (ISSN-L)
- OpenAlex
- W2182503946
- Cited by
- 64
- References
- 2
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.